Q3 2024 Masimo Corp Earnings Call Transcript
Key Points
- Masimo Corp (MASI) reported healthcare revenues of $343 million for the third quarter, representing a 12% growth compared to the previous year.
- The company achieved a consolidated non-GAAP operating profit of $81 million, marking a 23% growth year-over-year.
- Masimo Corp (MASI) is making significant progress on margin improvement initiatives, with a consolidated non-GAAP gross margin of 54% for the third quarter.
- The company is focusing on reallocating R&D resources to projects with the highest potential returns, which is expected to enhance long-term growth.
- Masimo Corp (MASI) has seen a 15% increase in unrecognized contract revenues, reaching $1.65 billion by the end of the third quarter, indicating strong market share gains.
- Non-healthcare revenues declined by 6% compared to the prior year, affected by a weakening environment for luxury consumer purchases and slowness in the housing market.
- The company is facing challenges in the non-healthcare segment, leading to a reduction in projected revenues by $20 million at the midpoint versus prior guidance.
- Masimo Corp (MASI) is undergoing a strategic review process for its consumer business, which could lead to uncertainties regarding its future structure and financial impact.
- The company has discontinued several projects, including noninvasive monitoring of cancer, bilirubin, and diabetes, due to lack of expected progress.
- Masimo Corp (MASI) is experiencing slowness in capital purchases from hospitals, which could impact future growth in the healthcare segment.
Good afternoon, ladies and gentlemen, and welcome to Masimo's third-quarter 2024 earnings conference call. The company's press release is available at www.masimo.com. (Operator Instructions)
I'm pleased to introduce Eli Kammerman, Masimo's Vice President of Business Development and Investor Relations.
Hello, everyone. Joining me today are interim CEO, Ms. Michelle Brennan; COO, Bilal Muhsin; and Executive Vice President and Chief Financial Officer, Micah Young.
This call will contain forward-looking statements, which reflect management's current judgment, including certain of our expectations regarding fiscal year 2024 and 2025 financial performance. However, they are subject to risks and uncertainties that could cause actual results to differ materially.
Risk factors that could cause our actual results to differ materially from our projections and forecasts are discussed in detail in our periodic filings with the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
